All Updates

All Updates

icon
Filter
Funding
Apogee Therapeutics raises USD 149 million in Series B funding
Precision Medicine
Dec 7, 2022
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Dec 7, 2022

Apogee Therapeutics raises USD 149 million in Series B funding

Funding

  • Biotechnology company Apogee Therapeutics raised USD 149 in an oversubscribed Series B funding round co-led by Deep Track Capital and RTW Investments, with participation from new and existing investors, including funds and accounts advised by Fidelity Management & Research Company, OrbiMed, and RA Capital Management. This brings the total funds raised by the company to USD 169 million. 

  • The new funds will be used to advance its lead program to clinical trials in 2023 and to expand its human resources including its leadership, scientific, and clinical teams. 

  • Founded in 2022, Apogee Therapeutics is a spin-off from Paragon Therapeutics and has a strategic collaboration with Paragon with exclusive rights to develop and commercialize antibodies. The company focuses on discovering and developing drugs targeting biological pathways to treat patients with immunological and inflammatory conditions. Further, the company plans to submit at least one Investigational New Drug application with the FDA for each year over three years starting in 2023. It has four programs in the pipeline and expects to release more information in 2023.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.